modelChlorambucil
Extends from Pharmacolibrary.Drugs.ATC.L.L01AA02.
Information
| name: | Chlorambucil | |
| ATC code: | L01AA02 | route: | oral |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 0.14 | L |
| clearance: | 0.2 | L/kg/hr |
| other parameters in model implementation | ||
Chlorambucil is an alkylating agent of the nitrogen mustard type, used primarily to treat chronic lymphocytic leukemia, Hodgkin's lymphoma, and other lymphoid malignancies. It acts by inhibiting DNA replication. While it was widely used in the past, its use has been largely replaced by newer agents in some indications, but it remains approved and in use for certain conditions.
Pharmacokinetics
Pharmacokinetic parameters reported in adult patients (both sexes) with malignant disease after oral administration. Main parameters from population PK studies and reviews.
References
Al-Nadaf, S, et al., & Burton, JH (2022). Population pharmacokinetics identifies rapid gastrointestinal absorption and plasma clearance of oral chlorambucil administered to cats with indolent lymphoproliferative malignancies. American journal of veterinary research 83(11) 1–9. DOI:10.2460/ajvr.22.06.0099 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36155936
Hoy, SM (2015). Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia. Drugs 75(3) 285–296. DOI:10.1007/s40265-014-0340-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25586272
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)